Quick Answer
BioAtla, Inc. reported Stockholders Equity of -$36.19 million for the year ending 2025.
- BioAtla, Inc. showed a decrease of -353.7% in Stockholders Equity from 2024 to 2025.
- This data is from BioAtla, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: -$56.01 million | Q1 2020: -$57.62 million | Q2 2020: -$63.84 million | Q3 2020: -$74.52 million | Q1 2021: $195.92 million | Q2 2021: $178.02 million | Q3 2021: $230.65 million | Q1 2022: $190.05 million | Q2 2022: $164.95 million | Q3 2022: $142.63 million | Q1 2023: $156.43 million | Q2 2023: $124.52 million | Q3 2023: $94.70 million | Q1 2024: $49.72 million | Q2 2024: $31.37 million | Q3 2024: $22.97 million | Q1 2025: $547.0 thousand | Q2 2025: -$16.75 million | Q3 2025: -$31.24 million.
- Over the full 6 years of available data (2020 to 2025), BioAtla, Inc.'s Stockholders Equity has declined by 117.2%.
- Historical annual values: Fiscal year 2025: -$36.19 million | Fiscal year 2024: $14.27 million | Fiscal year 2023: $70.67 million | Fiscal year 2022: $180.34 million | Fiscal year 2021: $210.82 million | Fiscal year 2020: $209.97 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: